| First Author | Stromnes IM | Year | 2015 |
| Journal | Cancer Cell | Volume | 28 |
| Issue | 5 | Pages | 638-652 |
| PubMed ID | 26525103 | Mgi Jnum | J:226758 |
| Mgi Id | MGI:5698542 | Doi | 10.1016/j.ccell.2015.09.022 |
| Citation | Stromnes IM, et al. (2015) T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell 28(5):638-52 |
| abstractText | Pancreatic ductal adenocarcinomas (PDAs) erect physical barriers to chemotherapy and induce multiple mechanisms of immune suppression, creating a sanctuary for unimpeded growth. We tested the ability of T cells engineered to express an affinity-enhanced T cell receptor (TCR) against a native antigen to overcome these barriers in a genetically engineered model of autochthonous PDA. Engineered T cells preferentially accumulate in PDA and induce tumor cell death and stromal remodeling. However, tumor-infiltrating T cells become progressively dysfunctional, a limitation successfully overcome by serial T cell infusions that resulted in a near-doubling of survival without overt toxicities. Similarly engineered human T cells lyse PDA cells in vitro, further supporting clinical advancement of this TCR-based strategy for the treatment of PDA. |
